Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on X:
“՛CRISPR-Cas9 Clinical Safety: Off-Target Assessment Framework — A recently published review highlights the need for advanced strategies to address off-target effects, the most significant challenge in therapeutic genome editing.
CRISPR-Cas9 Overview
CRISPR-Cas9 uses programmable nucleases comprising Cas9 endonuclease and guide RNA (gRNA) to create targeted double-strand breaks with base-pair precision. Current therapeutic applications include treating β-hemoglobinopathies via BCL11A enhancer targeting, demonstrated by Casgevy—the first FDA-approved CRISPR therapy.
Off-Target Effects -Critical Safety Challenge
Off-target activity occurs when CRISPR-Cas9 cleaves unintended genomic loci, potentially:
- Disrupting tumor suppressor genes or proto-oncogenes
- Generating large structural variants (deletions, inversions, translocations)
- Causing chromosomal instability and potential malignant transformation
Clinical reality: Over 100 active CRISPR clinical trials are underway, yet safety assessment protocols remain inconsistent.
Five-Tier Safety Assessment Framework
The authors propose a clear five-step safety evaluation:
1. Computational gRNA Design
In silico prediction tools identify potential off-target sites
High-fidelity Cas variants reduce off-target binding
2. Experimental Off-Target Nomination
Cell-free and cell-based assays provide genome-wide detection
Orthogonal validation using multiple methodologies
3. Structural Variant Detection
Long-read sequencing identifies large deletions and rearrangements
Digital PCR quantifies specific variants with high sensitivity
4. Functional Safety Assessment
In vitro transformation assays evaluate oncogenic potential
Single-cell sequencing links genotype to phenotype
5. Regulatory Compliance
GMP-grade manufacturing ensures consistent quality
FDA/EMA guidelines mandate comprehensive characterization
Personalized Safety Considerations
Population-specific variants can create or eliminate off-target sites. Solution: Variant-aware prediction tools incorporate individual genetic profiles to identify population-specific or patient-specific risks.
The Path Forward
Standardizing rigorous safety frameworks while maintaining innovation pace remains the key challenge. As CRISPR transitions from experimental tool to clinical standard, comprehensive off-target assessment becomes scientifically essential and ethically imperative for patient safety.
Congratulations to Nechama Kalter and co-authors.”
Read the full article here.
Title: Off-target effects in CRISPR-Cas genome editing for human therapeutics: Progress and challenges
Authors: Nechama Kalter, Carla Fuster-García, Alfredo Silva, Víctor Ronco-Díaz, Stefano Roncelli, Giandomenico Turchiano, Jan Gorodkin, Toni Cathomen, Karim Benabdellah, Ciaran Lee, Ayal Hendel
Stay updated on the latest scientific advances with Hemostasis Today.
-
Oct 7, 2025, 08:27John Chuback - Blood Clots: The Silent Killer
-
Oct 7, 2025, 04:20Nita Radhakrishnan to Present The First Indian Collaborative Data on Hemophilia from the WBDR Registry
-
Oct 6, 2025, 17:51Klaus Mönkemüller Just Released "The EndoCollab Guide for GI Bleeding" For Endoscopists
-
Oct 6, 2025, 08:10Haemophilia Foundation Australia: Animals Can Have Bleeding Disorders Too!
-
Oct 6, 2025, 08:03Peter Libby: Exploring Inflammation in Atherosclerosis: Lessons and Therapeutic Implications
-
Oct 7, 2025, 08:31Brooke Wolford Leads Groundbreaking GWAS Study Identifying Novel Genetic Loci for Venous Thromboembolism
-
Oct 7, 2025, 08:25ImmuneLink LLC Research: Role of Interferon-Gamma (IFN-γ) in Pathophysiology and Management of Deep Vein Thrombosis
-
Oct 7, 2025, 03:56Nathan Connell: Interesting Data in The Management of HAC Has Been Published in Blood from Benoit Guillet and Colleagues
-
Oct 7, 2025, 03:40Nature Communications Study by Amelia Haj and Colleagues Identifies Factor XII as a Safer Target for Anticoagulation
-
Oct 7, 2025, 03:36Lisiena Hysenaj: Excited to Announce the Jeroen Roose Lab’s Latest Publication from Laila Karra Khalil
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 3, 2025, 15:31Anirban Sen Gupta and Andrew Shoffstall Collaboration on Bioinspired Synthetic Platelet Systems for Brain Injury Treatment
-
Oct 3, 2025, 15:07Shai Shen-Orr: Excited to Share that The Human Immunome Project (HIP) Has Launched Its Scientific Partner Network
-
Oct 2, 2025, 04:59Caterina Casari - Prizes for Innovators 2025 Winner!
-
Oct 2, 2025, 04:572025 Innovators Award: Ile de France Région Recognizes 3 Researchers Who Have Committed Themselves to The Innovation
-
Oct 7, 2025, 08:29“48 Poems on 48 Blood Group Systems” - Dr Bhavyaa Beriwal Blends Science and Poetry in Her New Transfusion Medicine Book
-
Oct 7, 2025, 04:35Hema Tallman: During IPAW, We Honor The Unseen Heroes – Plasma Donors
-
Oct 7, 2025, 04:09Svenja Tatjana Barckhausen: Reducing Reliance on U.S. Plasma – Not Just for Europe, But for The World!
-
Oct 7, 2025, 03:58Louise Bannon: Don’t Wait Until You’re Diagnosed to Learn About Blood Clots
-
Oct 6, 2025, 07:40Erin VanDyke: World Thrombosis Day Falls Right At The End Of PA Week, And It’s A Powerful Reminder Of Why I Do What I Do